Apixaban is more effective than warfarin in reduction of the incidence of strokes and bleeding in patients with atrial fibrillation irrespective of their risk profiles: subanalysis of ARISTOTLE trial
2013
Abstract
ARISTOTLE trial compared efficacy and safety of apixaban 5 mg twice daily with warfarin in 18 201 patients with atrial fibrillation. The risk of arterial thromboembolism and bleeding according to CHADS2, CHA2DS2VASc, and HAS-BLED scores was calculated for all study subjects.
Apixaban significantly lowered the rate of stroke a systemic embolisation, decreased mortality and reduced the incidence of bleeding complications irrespective of the patients risk profiles.